Evidence map›Paper›PMID 29632489›Full record

ArticleFrontiers in pharmacology2018

Identification of Novel Melanin Synthesis Inhibitors From

Adamantia Agalou, Michael Thrapsianiotis, Apostolis Angelis, Athanasios Papakyriakou, Alexios-Leandros Skaltsounis, Nektarios Aligiannis, Dimitris Beis

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Characterizing Nanoparticle Isolated by Yam Bean (Pharmaceutical nanotechnology · 2025
    Article
  5. Article
  6. Review
  7. Anti-Melanogenic Effects ofMarine drugs · 2024
    Article
  8. Loss of REP1 impacts choroidal melanogenesis and vasculogenesis in choroideremia.Biochimica et biophysica acta. Molecular basis of disease · 2024
    Article
  9. Chemical Profile and Health-Promoting Activities ofPlants (Basel, Switzerland) · 2023
    Article
  10. The Potential ofAntioxidants (Basel, Switzerland) · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Crocins fromMolecules (Basel, Switzerland) · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adamantia AgalouZebrafish Disease Model Lab, Biomedical Research Foundation Academy of Athens, Athens, Greece.
Michael ThrapsianiotisDepartment of Pharmacognosy and Natural Product Chemistry, Faculty of Pharmacy, University of Athens, Athens, Greece.
Apostolis AngelisDepartment of Pharmacognosy and Natural Product Chemistry, Faculty of Pharmacy, University of Athens, Athens, Greece.
Athanasios PapakyriakouInstitute of Biosciences and Applications, National Centre of Scientific Research "Demokritos", Athens, Greece.
Alexios-Leandros SkaltsounisDepartment of Pharmacognosy and Natural Product Chemistry, Faculty of Pharmacy, University of Athens, Athens, Greece.
Nektarios AligiannisDepartment of Pharmacognosy and Natural Product Chemistry, Faculty of Pharmacy, University of Athens, Athens, Greece.
Dimitris BeisZebrafish Disease Model Lab, Biomedical Research Foundation Academy of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zebrafish has emerged as a powerful model organism for high throughput drug screening. Several morphological criteria, transgenic lines and

Indexed as

Crataegusdibenzofuranmelanin synthesis inhibitorsphenotype-driven screenszebrafish

Identifiers

PMID29632489
PMCPMC5879087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.